# Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

> **NCT00078949** · PHASE3 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 849 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** cisplatin
- **DRUG:** cytarabine
- **DRUG:** dexamethasone
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00078949
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08-27
- **Primary completion:** 2013-07-29
- **Final completion:** 2018-12
- **Target enrollment:** 849 (ACTUAL)
- **Last updated:** 2023-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078949, "Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00078949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*